2019 CYIR Finalized
3 MECHANISM Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmelé T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018; 3(5): e98960 Summary Prior work in sepsis suggests that a reduced number of cir- culating lymphocytes (i.e. lymphopenia) is associated with new opportunistic infections and greater mortality. However, it is unknown whether this is just an epiphenomenon of ill- ness severity or represents a key mechanistic role. Multiple murine studies suggest that apoptosis-resistant lympho- cytes improve sepsis survival after adoptive transfer, and that IL7 may be a key cytokine in lymphocyte proliferation and function. In this study, Francoise et al. conducted a prospective, multicenter, randomized, double-blind, place- bo-controlled phase IIb trial of CYT107, a recombinant IL7, in 27 patients with septic shock and severe lymphopenia of <900 lymphocytes/μl. The authors report that CYT107 was well-tolerated without inducing additional inflammation, sepsis-induced lymphopenia was reversed vs. placebo (3-4 fold increase in lymphocyte count), and that the proportion of circulating CD4+ and CD8+ T cells increased. CYT107 was administered via the intramuscular route for 2 differ- ent regimens, either a low frequency (once weekly) vs. high frequency (twice weekly). There were no increases in the frequency of clinically adjudicated secondary infections with CYT107 and no difference in mortality at 28 days. Comments 1. This trial is one of the first to test the “immune boosting” effects of a novel therapeutic rather than testing therapies that block inflammation and the host response. 2. The trial enrolled only 27 patients and was powered to detect differences biologic endpoints not patient centered outcomes. 3. This is the first trial to attempt to enhance adaptive immunity and reduce apoptotic cell death 4. Of those enrolled, the CD4+ T cell count was less than 200 cells/μl in more than 60% of patients, a criterion usually reserved for patient with HIV or AIDS. 5. These data suggest a transformational target for immunother- apy in sepsis, restoring adaptive immunity, and increasing the number of circulating CD4+ and CD8+ effector cells—worthy of larger randomized trial. CLINICAL TRIALS Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Correa M, Glass P, Harward M, Joyce C, Li Q, McArthur C, Perner A, Rhodes A, Thompson K, Webb S, Myburgh J; ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med. 2018; 378(9): 797-808 Summary For the past half century, the role of corticosteroid therapy in septic shock has remained controversial. Multiple random- ized trials, systematic reviews, and meta-analyses have not provided a definitive answer, and often note that prior trials were underpowered with a high risk of bias. This has result- ed in significant practice variability, and concern about potential adverse effects. In this study, Venkatesh and col- leagues report on the landmark Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) trial, an international, pragmatic, double-blind, parallel-group, randomized controlled trial that compared intravenous infusion of hydrocortisone (200 mg per day for 7 days) with matched placebo in 3800 patients with septic shock undergoing mechanical ventilation in an intensive care unit. They report similar baseline characteristics, time to initiation of study arm, and treatment adherence. They found no difference in the primary outcome of 90-day mor- tality between arms, as 511 of 1832 patients (27.9%) who had been assigned to receive hydrocortisone had died, and 526 of 1826 (28.8%) who had been assigned to receive pla- cebo (odds ratio=0.95; 95%CI=0.82-1.10, p=0.50). No dif- ference was present in any of the 6 pre-defined subgroups. The time to resolution of shock was shorter in the hydro- cortisone group vs. placebo (median 3 vs. 4 days, hazard ratio=1.32, 95%CI=1.23-1.41, p<0.001). More adverse SEPSIS AND SEPTIC SHOCK Christopher W. Seymour, MD, MSc University of Pittsburgh School of Medicine Department of Critical Care and Emergency Medicine, the CRISMA Center Pittsburgh, PA SUNDAY, MAY 19 SEPSIS AND SEPTIC SHOCK
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw